LY-3177833

SKU: orb1941074

Description

A potent and selective CDC7 inhibitor with IC50 of 3.3 nM.(In Vitro):LY3177833 (10 μM; 4 days) increases SA-β-gal content in Hep3B cells.(In Vivo):LY3177833 (Example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dose-dependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation.

Key Properties

• CAS Number: 1627696-51-8
• MW: 309.2978
• Purity: >98% (HPLC)
• Formula: C₁₆H₁₂FN₅O
• SMILES: O=C1N[C@@](C)(C2=NC=NC=C2F)C3=C1C=C(C4=CNN=C4)C=C3
• Target: CDK
• Solubility: DMSO: ≥ 30 mg/mL

Bioactivity

• In Vivo:
  LY3177833 (Example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dose-dependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation. Animal model: Female athymic Balb/c nude mice (5-6 weeks old) with SW620 cells. Dosage: 10.4 mg/kg, 20.8 mg/kg and 31.2 mg/kg. Administration: Oral gavage; twice a day for 2 weeks. Result: Showed dose dependent antitumor activity in SW620 mouse xenograft tumor model.
• In Vitro:
  LY3177833 (10 μM; 4 days) increases SA-β-gal content in Hep3B cells. Western blot analysis. Cell line: Hep3B cells. Concentration: 10 μM. Incubation time: 4 days. Result: Increased the expression of human SA-β-gal.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LY3177833

Quick Database Links

Gene Symbol

CDK